【双语】辉瑞“特效药”为何不愿放低姿态进医保？

从附条件获批至今，Paxlovid价格一直是行业各界以及民众所关注的焦点。2022年12月28日，有消息称Paxlovid医保支付价格已由2300元/盒下调至1890元/盒。

Since the conditional approval, the price of Paxlovid has always been the focus of the industry and the public. On December 28, 2022, it was reported that the payment price of Paxlovid medical insurance had been lowered from 2300 yuan/vial to 1890 yuan/vial.

近日又有新闻报道，上海多个社区卫生服务中心已有Paxlovid到货，医保报销后自费189元/盒，另据报道，目前上海部分社区卫生服务中心Paxlovid已经断货，也并非人人医保报销后均是189元/盒，每人报销比例不完全一样。

Recently, there was a news report that Paxlovid had arrived at several community health service centers in Shanghai, and after the medical insurance reimbursement, they paid 189 yuan/box at their own expense.

结果大家都看到了，2022年国家医保药品目录谈判工作于1月8日正式结束。本次医保谈判因辉瑞报价高未能成功。换言之，从4月份起，患者要使用该药的话，需要完全自费。近两千元一盒的药物，对于多数人而言，价格仍偏昂贵。

As you can see, the negotiation of the national medical insurance drug catalog in 2022 was officially completed on January 8. The medical insurance negotiation failed due to the high price offered by Pfizer. In other words, since April, if patients want to use the drug, they need to pay their own expenses. For most people, the price of nearly 2000 yuan a bottle of drugs is still too high.

市场人士分析做出了几大猜测：一是该药供不应求，药企不愁卖；二是辉瑞不愿意破坏自身全球价格体系；三是该药在疗效上显示出一定的优势，也成为当下新冠治疗首选药物，就算不降价，预计该药在细分人群使用上，仍有很大需求空间。

Market analysts have made several guesses: First, the supply of the drug exceeds the demand, and the drug companies are not worried about selling it; Second, Pfizer is unwilling to destroy its global price system; Third, the drug has shown certain advantages in efficacy, and has become the first choice for COVID-19 treatment. Even if the price is not reduced, it is expected that there will still be great demand for the drug in the use of small segments of the population.

我们应该看到，刨除以上原因，辉瑞的Paxlovid价格高昂貌似有一定的合理性，辉瑞公司披露的Paxlovid临床数据显示，Paxlovid可降低89%的住院和死亡风险。但是，我们更应该看到其鲜为人知的一面。那就是，在实际操作中，该药物常用于出现症状后的5天内。也就是说，该药物是防止向重症、危重症转移，而不是用来治疗重症、危重症的。另外，该药使用后有可能再次复阳。去年7月21日，美国总统拜登首次确诊感染新冠病毒，出现流鼻涕、嗓子痛、疲劳等症状。隔离期间，他持续服用抗病毒药物Paxlovid。27日，拜登新冠病毒检测结果为阴性，随后结束隔离。30日，拜登新冠病毒检测结果再次呈阳性。此外，当地时间8月15日，美国辉瑞公司首席执行官艾伯乐（Albert Bourla）新冠病毒检测结果呈阳性。他表示已经开始口服该公司的新冠抗病毒药物Paxlovid。9月24日，艾伯乐的新冠病毒检测再次呈阳性。

期待更多的人，尤其是患者，能站出来为国产药说话。